 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ICP-490 / InnoCare
Enrollment open: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=80, Recruiting, Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Not yet recruiting --> Recruiting
- ICP-490 / InnoCare
ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin (Room W224 - Convention Center) - Mar 14, 2023 - Abstract #AACR2023AACR_5527;
In various MM and NHL tumor models, it demonstrates superior tumor killing activities than currently approved IMiDs, including overcoming lenalidomide resistance. ICP-490 is now in phase I clinical trial.
- |||| ICP-490 / InnoCare
New P1/2 trial: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 9, 2023
P1/2, N=80, Not yet recruiting, Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.